ART to participate in FDA workshop on imaging technologies applied to drug development in Bethesda, Maryland

Major FDA initiative in promoting the use of imaging in drug development 
and clinical response to therapy

MONTREAL, May 5 /CNW Telbec/ - ART Advanced Research Technologies Inc.
("ART") (TSX: ARA), a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, will be participating in break out
sessions at an FDA workshop on the use of medical imaging as a drug
development tool, being held in Bethesda, Maryland, from May 5 to 6, 2005.
As part of the FDA's Critical Path Initiative, imaging technologies are
considered to be at the forefront of efforts to apply new strategies and
technologies streamlining the drug-approval process.
"In this context, ART addresses a large unmet need within the
pharmaceutical industry with its Time Domain (TD) optical imaging technology,
using the power of optical molecular imaging to accelerate the delivery of
better therapies and cures," said Micheline Bouchard, ART's President and CEO.
Two products based on ART's technology platform - eXplore Optix and
SoftScan - target two different but related markets: preclinical research and
breast cancer diagnosis. These products have the potential to span the entire
continuum of drug development: from the analysis of new compounds in
laboratory animals, through to the diagnosis of disease and to the monitoring
of a treatment's efficacy. SoftScan is intended to give the clinician new
optical imaging tools for a better diagnosis of breast cancer and will grow to
provide a platform for testing molecular imaging compounds in humans.

About ART

ART Advanced Research Technologies Inc. is a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries. ART has
developed two products based on its innovative technology. The first is
eXplore Optix(TM), a molecular imaging device designed for monitoring
physiological changes in living systems at the preclinical study phases of new
drugs. eXplore Optix(TM) is distributed by GE Healthcare and is used by
industry and academic leaders worldwide to bring new and better treatments to
patients faster. The second is SoftScan(R), a medical imaging device designed
to improve the diagnosis and treatment of breast cancer. ART is
commercializing its products in a global strategic alliance with GE
Healthcare, a world leader in mammography and imaging. ART's shares are listed
on the TSX under the ticker symbol ARA. Visit ART online at www.art.ca

This press release may contain forward-looking statements subject to
risks and uncertainties that would cause actual events to differ materially
from expectations. These risks and uncertainties are described in ART Advanced
Research Technologies Inc.'s regulatory filings with Canadian Securities
Commissions.